Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Rozerem Recommended for Approval
February 8, 2010
- DSP to Transfer Growth Hormone Business to JCR
February 8, 2010
- PMDA Needs Internal Renovation: Prof. Kami
February 8, 2010
- Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada
February 8, 2010
- Panel on Unapproved Drugs to Hold 1st Meeting
February 8, 2010
- Kyowa Kirin Aims at Pharm. Sales of \225.0 Bil. in FY2012
February 8, 2010
- Medical Fees Up for the 1st Time in 10 Years, But Drug Prices Down 6.5%
February 8, 2010
- Zeria to Overcome NHI Price Cuts through Synergism with Tillotts: President Ibe
February 8, 2010
- Present Scientific Grounds for Combination Drugs
February 8, 2010
- GLP-1 Analogues to Be Recommended for Severe DM
February 1, 2010
- Teva-Kowa Acquires 2/3 of Taisho Pharm's Shares
February 1, 2010
- NIHS's Working Group Finds No Problems with Generics of 9 APIs
February 1, 2010
- Sciele Pharma Renamed Shionogi Pharma
February 1, 2010
- EPO's Biosimilar Approved: JCR, Kissei
February 1, 2010
- Kyowa Kirin Revises Business Forecasts Downward
February 1, 2010
- JGA President Expresses Hope for the New Pricing System
February 1, 2010
- Iwaki Posts Net Losses Two Years in a Row
February 1, 2010
- High Out-of-Pocket Expenses Cited by 38.4% of Households Not Seeing Doctor
February 1, 2010
- 29 Products Approved Including Japan's 1st GLP-1 Analogue
February 1, 2010
- Ethical Drugs Show Double-Digit Growth for the First Time in FY2009: Crecon
February 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…